Growing evidence indicates that chemokines participate in the generation and maintenance of bone cancer pain (BCP). Recent work in Exp Neurol by Guan et al. (2015) demonstrated the involvement of spinal chemokine receptor CXCR3 and its downstream PI3K/Akt and Raf/MEK/ERK signaling pathways in BCP. This work provides new evidence to support that chemokines participate in central sensitization in BCP condition. Reviewed evidence suggests that few chemokines have been proved to be related to cancer pain. The underlying relationship between CXCR3 signaling and BCP condition requires further study. (C) 2015 Elsevier Inc. All rights reserved.
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Anesthesiol, Tongji Med Coll, Wuhan 430030, Peoples R China
通讯作者：
通讯机构：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Anesthesiol, Tongji Med Coll, Wuhan 430030, Peoples R China[*1]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Anesthesiol, Tongji Med Coll, 1095 Jiefang Rd, Wuhan 430030, Peoples R China
推荐引用方式(GB/T 7714)：
Guo Genhua,Gao Feng.CXCR3: Latest evidence for the involvement of chemokine signaling in bone cancer pain[J].EXPERIMENTAL NEUROLOGY.2015,265:176-179.doi:10.1016/j.expneurol.2015.02.003.
APA：
Guo, Genhua&Gao, Feng.(2015).CXCR3: Latest evidence for the involvement of chemokine signaling in bone cancer pain.EXPERIMENTAL NEUROLOGY,265,
MLA：
Guo, Genhua,et al."CXCR3: Latest evidence for the involvement of chemokine signaling in bone cancer pain".EXPERIMENTAL NEUROLOGY 265.(2015):176-179
